1.Management of advanced thymoma presenting with myasthenia gravis in a resource-limited setting: A case report
I Wayan Losen Adnyana ; Dian Daniella
Acta Medica Philippina 2024;58(Early Access 2024):1-6
Thymomas are rare tumours which generally account for only 0.2 – 1.5% of mediastinal tumours in adults. Around 40% of patients present with systemic symptoms such as motor weakness due to myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. Based on recent guidelines, management of advanced thymoma uses a multimodal approach, which is thymectomy followed by radiotherapy, but not all health care centers have radiotherapy facilities.
A 52-year-old woman presented with nasal voice and had difficulty swallowing food. Patient was diagnosed with myasthenia gravis (MG). CT scan with contrast of the thorax showed a heterogenous solid mass in anterior mediastinum. Histopathological examination showed thymoma type B2. Thymectomy followed by seven cycles of platinum-based chemotherapy were done on the patient. Evaluation afterward showed complete remission of thymoma. The patient’s motor weakness improved after the chemotherapy. Post-chemotherapy period was uneventful at six months on follow-up visit. The dosage of acetylcholinesterase inhibitor drug is reduced periodically due to improvement in motor weakness.
The case emphasizes how to manage an advanced thymoma with MG with limited therapeutic options, and the
importance of multidisciplinary management involving oncologists, surgeons, and neurologists.
Thymoma
;
Myasthenia Gravis
;
Drug Therapy
;
Thymectomy
2.Acupuncture for 9 cases of ocular myasthenia gravis.
Chinese Acupuncture & Moxibustion 2014;34(11):1081-1082
Acupuncture Points
;
Acupuncture Therapy
;
Adult
;
Aged
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myasthenia Gravis
;
therapy
3.Exploration on the diagnosis and treatment of generalized myasthenia gravis with acupuncture and moxibustion based on the study of ancient medical works.
Zi-Kai JIN ; Bing GAO ; Li-da ZHANG ; Zi-Wei GUO ; Meng SUN ; Rong-Lin CAI ; Shu-Ping NIU ; Ling HU ; Wei TANG
Chinese Acupuncture & Moxibustion 2021;41(7):819-822
Through collecting the relevant provisions and medical cases of
Acupuncture
;
Acupuncture Points
;
Acupuncture Therapy
;
Humans
;
Meridians
;
Moxibustion
;
Myasthenia Gravis/therapy*
4.Acupuncture combined with western medication for ocular myasthenia gravis: a randomized controlled trial.
Xian-Peng XU ; Yan-Bing JIANG ; Li-Hua GUAN ; Qing-Jie JI ; Ying JIN
Chinese Acupuncture & Moxibustion 2022;42(7):755-759
OBJECTIVE:
To compare the clinical efficacy between acupuncture combined with western medication and simple western medication for ocular myasthenia gravis (OMG), and to explore its possible mechanism.
METHODS:
A total of 60 patients of ocular myasthenia gravis were randomized into an acupuncture combined with western medication group (30 cases, 1 case dropped off) and a western medication group (30 cases, 2 cases dropped off). Oral pyridostigmine bromide tablet and prednisone acetate tablet were given in the western medication group. On the basis of the treatment in the western medication group, Tongdu Tiaoqi acupuncture (acupuncture for unblocking the governor vessel and regulating qi ) was applied at Baihui (GV 20), Fengfu (GV 16), Hegu (LI 4), Zusanli (ST 36), etc. in the acupuncture combined with western medication group, once a day, 6 days a week. The treatment was given 8 weeks in both groups. Before and after treatment, the OMG clinical absolute score was observed, electrophysiological indexes of orbicularis oculi (value of mean jitter, percentage of jitter >55 μs and percentage of blocks) were measured by single-fiber electromyography (SFEMG), serum levels of acetylcholine receptor antibody (AChR-Ab), interferon-gamma (IFN-γ) and interleukin-4 (IL-4) were detected by ELISA method.
RESULTS:
After treatment, the OMG clinical absolute scores, values of mean jitter, percentages of jitter >55 μs, percentages of blocks and serum levels of AChR-Ab, IFN-γ and IL-4 were decreased compared before treatment in both groups (P<0.05), and those in the acupuncture combined with western medication group were lower than the western medication group (P<0.05).
CONCLUSION
Acupuncture combined with western medication can effectively improve ptosis, palpebra superior fatigability, eye movement disorder and neuromuscular junction dysfunction in patients with ocular myasthenia gravis, the therapeutic effect is superior to simple western medication. Its mechanism may be related to down-regulating serum levels of AChR-Ab, IFN-γ and IL-4 and promoting the recovery of orbicularis oculi function.
Acupuncture Therapy
;
Facial Muscles
;
Humans
;
Interferon-gamma
;
Interleukin-4
;
Myasthenia Gravis/drug therapy*
5.Surgical Treatment of Thymoma.
Chi Uk HONG ; Joo Cheol PARK ; Myung Chun KIM ; Kyu Seok CHO ; Seh Young YOO
The Korean Journal of Thoracic and Cardiovascular Surgery 1997;30(1):61-66
Between January 1986 and December 1995, 24 patients were treated surgically for thymoma. There were 17 males and 7 females, and their ages ranged from 23 to 69 years old and mean age was 49 years. Thymomas were associated with fourteen my asthenia gravis, and classified histologically as lymphocytic in 12 patients, mixed in 8, epithelial in 4, and classified clinically as stage I in 11, stage II in 4, stage III in 8 and stage VI in 1 patient. Eleven patients with non-invasive thymoma had received surgical resection, and 10 out of 13 patients with invasive thymoma were able to undergo complete resection. A partial resection or tissue biopsy followed by radiation or chemotherapy was done with the remaining three patients. Three died, four had improvement of symptom, two had relapse and fifteen had no symptom during follow up ranged from 25 days to 60 months. In fourteen cases of thymoma with myasthenia gravis, one died due to myasthenic crisis, two showed symptom aggravation, six had less medical treatment and five patients had medical treatment as same as dosage received preoperatively.
Aged
;
Asthenia
;
Biopsy
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Myasthenia Gravis
;
Recurrence
;
Thymoma*
6.Myasthenia Gravis, Schizophrenia, and Colorectal Cancer in A Patient: Long-Term Follow-Up with Medication Complexity.
Haebin KIM ; Minha HONG ; Geon Ho BAHN
Psychiatry Investigation 2013;10(3):300-302
In a case of 46-year-old woman suffering from schizophrenia for over 20 years, she experienced frequent episodes of dyspnea and confirmed as superimposed with myasthenia gravis (MG). Throughout the seven-year follow-up period, after diagnosed as MG, she has been hospitalized 6 times and also diagnosed as colorectal cancer. Authors experienced various conditions associated with untoward effects of medication for myasthenia, schizophrenia, and colorectal cancer. Therefore, authors reported considerations for the pharmacotherapy of schizophrenia with myasthenia gravis.
Colorectal Neoplasms*
;
Drug Therapy
;
Dyspnea
;
Female
;
Follow-Up Studies*
;
Humans
;
Middle Aged
;
Myasthenia Gravis*
;
Schizophrenia*
7.Research Advances in Ocular Myasthenia Gravis.
Ya Jun WU ; Li YAN ; Yu Xiang HU ; Jie RAO ; Xiao Xuan XU ; Yi CHENG ; Na WU ; Xiao Rong WU
Acta Academiae Medicinae Sinicae 2019;41(3):402-407
Ocular myasthenia gravis(OMG)is an autoimmune disease caused by neuromuscular junction transmission disorders and manifested mainly as fluctuating blepharoptosis and diplopia,with the extraocular muscles as the main involveed sites.While the pathogenesis of OMG remains unclear,some antibodies,complements,and cytokines may be the contributing factors.The diagnosis and treatment of OMG have been defined in recent years.This article reviews the pathogenesis,diagnosis,and treatment of OMG.
Antibodies
;
Complement System Proteins
;
Cytokines
;
Humans
;
Myasthenia Gravis
;
diagnosis
;
pathology
;
therapy
;
Oculomotor Muscles
;
pathology
8.Clinical Analysis of Surgical Treatment and Risk Factors of Thymoma.
Cheong LIM ; Sook Whan SUNG ; Joo Hyun KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 1997;30(1):67-71
Though thymoma is considered benign in a histopathologic specimen, its unusual behavior makes it important for surgeons to manage this neoplasm as cancerous lesion. Hence we clinically analysed the surgical cases of thymoma in our hospital, and we suggest the risk factors for its prognosis. From January 1987 to December 1994, we experienced 41 surgical cases of thymoma, excluding thymic carcinoma and cysts. There were 21 male and 20 female; age ranged from 16 to 64 years. Among them, myasthenia gravis was present in 22 patients (53.7%). Surgical treatment consisted of complete resection in 31 patients, partial resection in 7 patients, and biopsy only in 3 patients. According to Masaoka's classification, there were 27 patients in stage I, 4 patients in stage II, and 10 patients in stage III. Histopathology was of epithelial type in 14 patients, lymphocytic type in 11, and mixed type in 19. Eleven patients had adjuvant radiotherapy, chemotherapy, or both and there was no surgical mortality. Postoperative follow-up ranged from 1 to 88 months (mean 36 months) and three patients died and 5 patients suffered recurrences during the follow-up period. Postoperative risk factors were advanced Masaoka stage, invasiveness, and surgical method.
Biopsy
;
Classification
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Mortality
;
Myasthenia Gravis
;
Prognosis
;
Radiotherapy, Adjuvant
;
Recurrence
;
Risk Factors*
;
Thymoma*
9.Appearance of Systemic Lupus Erythematosus in Patients with Myasthenia Gravis following Thymectomy : Two Case Reports.
Mi Jeong PARK ; Yun A KIM ; Shin Seok LEE ; Byeong Chae KIM ; Myeong Kyu KIM ; Ki Hyun CHO
Journal of Korean Medical Science 2004;19(1):134-136
We report two cases of systemic lupus erythematosus (SLE) in myasthenia gravis (MG) patients who had undergone thymectomy. SLE developed in the patients 3 months or 13 yr after thymectomy, and polyarthritis was the main clinical manifestation of SLE. Both patients fulfilled at least four of the revised criteria for the classification of SLE. In this report, we describe two postthymectomy lupus patients and perform a comparative review of previous cases.
Adult
;
Female
;
Human
;
Lupus Erythematosus, Systemic/*diagnosis/etiology
;
Myasthenia Gravis/*diagnosis/therapy
;
Thymus Gland/*surgery
;
Time Factors
10.Childhood-onset myasthenia gravis: the analysis of influencing factors of therapeutic effect and prognosis.
Ning-ning QIN ; Rui-ling CHEN ; Shan MA ; Xiao-jun ZHANG ; Hou-liang SUN ; Yun JING
Chinese Journal of Pediatrics 2011;49(5):371-375
OBJECTIVEThough myasthenia gravis (MG) is a typical autoimmune disorder, there was some controversy on the treatment of the childhood-onset MG. By observing the efficacy of different therapies, the authors analyzed the affecting factors of prognosis in childhood-onset MG.
METHODThe retrospective data of 155 patients with childhood-onset MG (age of MG onset was less than 15 years) were collected from Department of Neurology, Beijing Tongren Hospital (January 2000 - February 2010). The patients were non-randomly divided according to their treatment into 3 groups (glucocorticoid, thymectomy and glucocorticoid combined with thymectomy groups). Postintervention status meeting the criteria of Myasthenia Gravis Foundation of America (MGFA) "complete stable remission, CSR", "pharmacologic remission, PR", "minimal manifestations, MM", or "Improved, I" was regarded as desirable response, which was used as primary indicator of observation. The authors assessed the efficacy of three therapies and analyzed the influencing factors of prognosis by using Chi-square test and Logistic regression.
RESULTAt 3 months of treatment, glucocorticoid group showed the highest effective rate. At the end of 1 year or 2 years of treatment, glucocorticoid combined with thymectomy group showed the highest effective rate respectively. The generalization rate of MG at 2 years, 10 years and 20 years in childhood-onset ocular MG patients were 4.3%, 10.7%, and 41.5%, respectively. Of patients with generalization of MG, 48.1% occurred within 2 years, 92.6% within 20 years. Univariate analysis showed that in childhood-onset ocular MG patients, variables such as age at onset (> 10 years), LG-MG and with chronic fatigue were significantly associated with general MG conversion. Whereas multivariate analysis showed that patients with age at onset (> 10 years) and chronic muscle fatigue were apt to convert to generalized MG.
CONCLUSIONGlucocorticoid appeared to have an effect that leads to early remission of symptoms in childhood-onset MG patients and glucocorticoid combined with thymectomy appeared to have better long-term effect. For those childhood-onset ocular MG patients with longer course of disease, older age of onset, chronic fatigue, or LG-MG, physicians should try to prevent the generalization of MG by immunosuppressive therapies.
Adolescent ; Child ; Child, Preschool ; Female ; Glucocorticoids ; therapeutic use ; Humans ; Male ; Myasthenia Gravis ; diagnosis ; therapy ; Prognosis ; Retrospective Studies ; Thymectomy ; Young Adult